HighTower Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

HighTower Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100	Closed	-$2.85K	–	4059
2023 Q4	$2.85K	Buy	+100	New	+$7.43K	﹤0.01%	3496
2022 Q3	–	Sell	-100	Closed	-$1K	–	3434
2022 Q2	$1K	Buy	+100	New	+$7.51K	﹤0.01%	3211
2022 Q1	–	Sell	-3	Closed	-$1K	–	3722
2021 Q4	$1K	Buy	+3	New	+$362	﹤0.01%	3275
2021 Q2	–	Sell	-22	Closed	-$7K	–	3419
2021 Q1	$7K	Buy	+22	New	+$3.29K	﹤0.01%	2945
2020 Q4	–	Sell	-1,000	Closed	-$3K	–	2952
2020 Q3	$3K	Buy	+1,000	New	+$112K	﹤0.01%	2495
2020 Q2	–	Sell	-1,000	Closed	-$6K	–	2553
2020 Q1	$6K	Buy	+1,000	New	+$88.5K	﹤0.01%	2142
2017 Q1	–	Sell	-19,000	Closed	-$1K	–	2174
2016 Q4	$1K	Buy	+19,000	New	+$1.17M	﹤0.01%	1925

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

HighTower Advisors's XBI Position: Q2 2026 in Review

HighTower Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 11% in Q2 2026, buying an estimated $1.19M and bringing the position to 90,861 shares worth $14.4M. The position accounts for 0.01% of the portfolio, ranked #779.

HighTower Advisors first reported a position in XBI in Q2 2013 and has held it in 49 quarters since. The position peaked at $42M in Q2 2022. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

HighTower Advisors held 90,861 shares of State Street SPDR S&P Biotech ETF worth $14.4M as of Q2 2026.
HighTower Advisors bought 8,780 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $1.19M.
State Street SPDR S&P Biotech ETF made up 0.01% of HighTower Advisors's portfolio in Q2 2026, its #779 holding.
HighTower Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 49 quarters since.
HighTower Advisors's State Street SPDR S&P Biotech ETF position peaked at $42M in Q2 2022.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.